These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
263 related articles for article (PubMed ID: 27615411)
41. Interstitial lung diseases associated with amyopathic dermatomyositis. Suda T; Fujisawa T; Enomoto N; Nakamura Y; Inui N; Naito T; Hashimoto D; Sato J; Toyoshima M; Hashizume H; Chida K Eur Respir J; 2006 Nov; 28(5):1005-12. PubMed ID: 16837503 [TBL] [Abstract][Full Text] [Related]
42. Increased ferritin predicts development and severity of acute interstitial lung disease as a complication of dermatomyositis. Gono T; Kawaguchi Y; Hara M; Masuda I; Katsumata Y; Shinozaki M; Ota Y; Ozeki E; Yamanaka H Rheumatology (Oxford); 2010 Jul; 49(7):1354-60. PubMed ID: 20385617 [TBL] [Abstract][Full Text] [Related]
43. The efficacy of tacrolimus in patients with interstitial lung diseases complicated with polymyositis or dermatomyositis. Kurita T; Yasuda S; Oba K; Odani T; Kono M; Otomo K; Fujieda Y; Oku K; Bohgaki T; Amengual O; Horita T; Atsumi T Rheumatology (Oxford); 2015 Jan; 54(1):39-44. PubMed ID: 24764266 [TBL] [Abstract][Full Text] [Related]
44. RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: Association with rapidly progressive interstitial lung disease. Sato S; Hoshino K; Satoh T; Fujita T; Kawakami Y; Fujita T; Kuwana M Arthritis Rheum; 2009 Jul; 60(7):2193-200. PubMed ID: 19565506 [TBL] [Abstract][Full Text] [Related]
45. Differences in clinical features and prognosis of interstitial lung diseases between polymyositis and dermatomyositis. Fujisawa T; Suda T; Nakamura Y; Enomoto N; Ide K; Toyoshima M; Uchiyama H; Tamura R; Ida M; Yagi T; Yasuda K; Genma H; Hayakawa H; Chida K; Nakamura H J Rheumatol; 2005 Jan; 32(1):58-64. PubMed ID: 15630726 [TBL] [Abstract][Full Text] [Related]
46. The efficacy and safety of tacrolimus on top of glucocorticoids in the management of IIM-ILD: A retrospective and prospective study. Chen Y; Bai Z; Zhang Z; Hu Q; Zhong J; Dong L Front Immunol; 2022; 13():978429. PubMed ID: 36119045 [TBL] [Abstract][Full Text] [Related]
47. Interstitial lung disease in patients with polymyositis, dermatomyositis and amyopathic dermatomyositis. Kang EH; Lee EB; Shin KC; Im CH; Chung DH; Han SK; Song YW Rheumatology (Oxford); 2005 Oct; 44(10):1282-6. PubMed ID: 15972351 [TBL] [Abstract][Full Text] [Related]
48. Clinically Amyopathic Dermatomyositis with Interstitial Pneumonia That Was Successfully Treated with Plasma Exchange. Yagishita M; Kondo Y; Terasaki T; Terasaki M; Shimizu M; Honda F; Oyama A; Takahashi H; Yokosawa M; Asashima H; Hagiwara S; Tsuboi H; Matsumoto I; Sumida T Intern Med; 2018 Jul; 57(13):1935-1938. PubMed ID: 29491297 [TBL] [Abstract][Full Text] [Related]
49. Clinical and laboratory features of fatal rapidly progressive interstitial lung disease associated with juvenile dermatomyositis. Kobayashi N; Takezaki S; Kobayashi I; Iwata N; Mori M; Nagai K; Nakano N; Miyoshi M; Kinjo N; Murata T; Masunaga K; Umebayashi H; Imagawa T; Agematsu K; Sato S; Kuwana M; Yamada M; Takei S; Yokota S; Koike K; Ariga T Rheumatology (Oxford); 2015 May; 54(5):784-91. PubMed ID: 25288783 [TBL] [Abstract][Full Text] [Related]
50. Short-term and long-term outcomes of interstitial lung disease in polymyositis and dermatomyositis: a series of 107 patients. Marie I; Hatron PY; Dominique S; Cherin P; Mouthon L; Menard JF Arthritis Rheum; 2011 Nov; 63(11):3439-47. PubMed ID: 21702020 [TBL] [Abstract][Full Text] [Related]
51. Predictive factors and unfavourable prognostic factors of interstitial lung disease in patients with polymyositis or dermatomyositis: a retrospective study. Ji SY; Zeng FQ; Guo Q; Tan GZ; Tang HF; Luo YJ; Tang ZQ; Han YF Chin Med J (Engl); 2010 Mar; 123(5):517-22. PubMed ID: 20367973 [TBL] [Abstract][Full Text] [Related]
52. Two Distinct Immune Cell Signatures Predict the Clinical Outcomes in Patients With Amyopathic Dermatomyositis With Interstitial Lung Disease. Ye Y; Zhang X; Li T; Ma J; Wang R; Wu C; Wang R; Bao C; Ye S; Shen N; Guo Q; Fu Q; Zhang X Arthritis Rheumatol; 2022 Nov; 74(11):1822-1832. PubMed ID: 35713981 [TBL] [Abstract][Full Text] [Related]
53. Body size-adjusted dose analysis of pirfenidone in patients with interstitial pneumonia. Uehara M; Enomoto N; Oyama Y; Suzuki Y; Kono M; Furuhashi K; Fujisawa T; Inui N; Nakamura Y; Suda T Respirology; 2018 Mar; 23(3):318-324. PubMed ID: 28851013 [TBL] [Abstract][Full Text] [Related]
54. Dysregulation of the type I interferon system in adult-onset clinically amyopathic dermatomyositis has a potential contribution to the development of interstitial lung disease. Sun WC; Sun YC; Lin H; Yan B; Shi GX Br J Dermatol; 2012 Dec; 167(6):1236-44. PubMed ID: 23013528 [TBL] [Abstract][Full Text] [Related]
55. Pirfenidone in idiopathic pulmonary fibrosis: real-life experience from a German tertiary referral center for interstitial lung diseases. Oltmanns U; Kahn N; Palmowski K; Träger A; Wenz H; Heussel CP; Schnabel PA; Puderbach M; Wiebel M; Ehlers-Tenenbaum S; Warth A; Herth FJ; Kreuter M Respiration; 2014; 88(3):199-207. PubMed ID: 25115833 [TBL] [Abstract][Full Text] [Related]
56. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Noble PW; Albera C; Bradford WZ; Costabel U; Glassberg MK; Kardatzke D; King TE; Lancaster L; Sahn SA; Szwarcberg J; Valeyre D; du Bois RM; Lancet; 2011 May; 377(9779):1760-9. PubMed ID: 21571362 [TBL] [Abstract][Full Text] [Related]
57. Case Report: Successful Treatment of Refractory Interstitial Lung Disease With Cyclosporine A and Pirfenidone in a Child With SLE. Deng L; Chen Y; Hu X; Zhou J; Zhang Y Front Immunol; 2021; 12():708463. PubMed ID: 34671344 [TBL] [Abstract][Full Text] [Related]
58. Prognostic significance of anti-aminoacyl-tRNA synthetase antibodies in polymyositis/dermatomyositis-associated interstitial lung disease: a retrospective case control study. Hozumi H; Enomoto N; Kono M; Fujisawa T; Inui N; Nakamura Y; Sumikawa H; Johkoh T; Nakashima R; Imura Y; Mimori T; Suda T PLoS One; 2015; 10(3):e0120313. PubMed ID: 25789468 [TBL] [Abstract][Full Text] [Related]
59. Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis. Nathan SD; Albera C; Bradford WZ; Costabel U; du Bois RM; Fagan EA; Fishman RS; Glaspole I; Glassberg MK; Glasscock KF; King TE; Lancaster L; Lederer DJ; Lin Z; Pereira CA; Swigris JJ; Valeyre D; Noble PW; Wells AU Thorax; 2016 May; 71(5):429-35. PubMed ID: 26968970 [TBL] [Abstract][Full Text] [Related]
60. Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis. Gono T; Sato S; Kawaguchi Y; Kuwana M; Hanaoka M; Katsumata Y; Takagi K; Baba S; Okamoto Y; Ota Y; Yamanaka H Rheumatology (Oxford); 2012 Sep; 51(9):1563-70. PubMed ID: 22589330 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]